Orchestra BioMed Holdings, Inc.

NasdaqGM:OBIO Stock Report

Market Cap: US$105.0m

Orchestra BioMed Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

David Hochman

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage31.1%
CEO tenure7yrs
CEO ownership1.1%
Management average tenure2.1yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

Health Check: How Prudently Does Orchestra BioMed Holdings (NASDAQ:OBIO) Use Debt?

Apr 04
Health Check: How Prudently Does Orchestra BioMed Holdings (NASDAQ:OBIO) Use Debt?

Here's Why We're Watching Orchestra BioMed Holdings' (NASDAQ:OBIO) Cash Burn Situation

Dec 18
Here's Why We're Watching Orchestra BioMed Holdings' (NASDAQ:OBIO) Cash Burn Situation

Orchestra BioMed Holdings (NASDAQ:OBIO) Has Debt But No Earnings; Should You Worry?

Mar 01
Orchestra BioMed Holdings (NASDAQ:OBIO) Has Debt But No Earnings; Should You Worry?

CEO Compensation Analysis

How has David Hochman's remuneration changed compared to Orchestra BioMed Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$2mUS$595k

-US$61m

Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$56m

Mar 31 2024n/an/a

-US$52m

Dec 31 2023US$7mUS$595k

-US$49m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$39m

Dec 31 2022US$3mUS$395k

-US$34m

Sep 30 2022n/an/a

-US$32m

Jun 30 2022n/an/a

-US$27m

Mar 31 2022n/an/a

-US$25m

Dec 31 2021US$710kUS$395k

-US$23m

Compensation vs Market: David's total compensation ($USD1.91M) is above average for companies of similar size in the US market ($USD670.70K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Hochman (49 yo)

7yrs

Tenure

US$1,912,475

Compensation

Mr. David P. Hochman is Founder & Director at Orchestra BioMed Holdings Inc. (formerly known as Health Sciences Acquisitions Corporation 2) since May 2018 and serves as its Chief Executive Offer and Chairm...

Leadership Team

NamePositionTenureCompensationOwnership
David Hochman
Founder7yrsUS$1.91m1.09%
$ 1.1m
Darren Sherman
Founder7yrsUS$1.79m0.52%
$ 551.1k
Andrew Taylor
Chief Financial Officer1.9yrsUS$1.06m0.16%
$ 167.8k
William Little
Executive Vice President of Corporate Development & Strategy1.9yrsno data0.80%
$ 843.5k
Yuval Mika
GM & CTO of Bioelectronic Therapies7yrsno data0.13%
$ 135.8k
Hans-Peter Stoll
Chief Clinical Officer3.1yrsno datano data
Avraham Fischer
Senior Vice President of Medical Affairs & Innovation2.3yrsno datano data
Bob Laughner
Senior Vice President of Regulatory & Quality1.5yrsno datano data
Juan Lorenzo
Senior Vice President of Product Development1.5yrsno datano data
Mark Pomeranz
GM & Executive VP of Interventional Therapiesless than a yearno datano data
Joshua Aiello
Corporate Controllerno datano datano data

2.1yrs

Average Tenure

53yo

Average Age

Experienced Management: OBIO's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Hochman
Founder7yrsUS$1.91m1.09%
$ 1.1m
Darren Sherman
Founder7yrsUS$1.79m0.52%
$ 551.1k
Paul Teirstein
Member of Medical Advisors Boardno datano datano data
Vivek Reddy
Member of Medical Advisors Boardno datano datano data
Eric Fain
Independent Lead Director6.5yrsUS$220.00k0.094%
$ 98.2k
Robert Schwartz
Member of Medical Advisors Boardno datano datano data
Jason Aryeh
Independent Director6.5yrsUS$190.00k0.19%
$ 204.6k
Stefan Verheye
Member of Medical Advisors Boardno datano datano data
Roger de la Torre
Member of Medical Advisors Boardno datano datano data
Pieter Stella
Member of Medical Advisors Boardno datano datano data
Pamela Connealy
Independent Director5.3yrsUS$190.00k0.011%
$ 11.6k
Karl-Heintz Kuck
Member of Medical Advisors Boardno datano datano data

6.5yrs

Average Tenure

56yo

Average Age

Experienced Board: OBIO's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 10:42
End of Day Share Price 2025/05/05 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Orchestra BioMed Holdings, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew MiksicBarclays
Kyle BauserB. Riley Securities, Inc.
Anderson SchockB. Riley Securities, Inc.